Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5542 | Ordered by Date (descending)
1 2 3 ... 25 26 27 ... 54 55 56

Deal: Collaboration or Financing	Date
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures	2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp	2015-01-01
Mérieux–Copan: sample prep automation, 201501– collab distribution of WASP + WASPLab systems by bioMérieux starting in FR+DE+UK + to be expanded	2015-01-01
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI	2015-01-01
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI	2015-01-01
Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder	2015-01-01
Oncgnostics–MDxHealth: PCR technology, 201501– license ww non-excl for MSP technology for cervical cancer diagnostics to Oncgnostics	2015-01-01
Padlock Therapeutics–Evotec: drug discovery services, 201501–201703 extension of collab to deliver multiple PAD inhibitor development candidates	2015-01-01
ProteoMedix–SEVERAL: investment, 201501 2nd closing of financing round Series B CHF1m bringing total round to CHF4.2m	2015-01-01
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research	2015-01-01
Seres Therapeutics–Nestlé: investment, 201501 equity investment by Nestlé Health Science	2015-01-01
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB	2015-01-01
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme	2015-01-01
Enzymatics–Qiagen: investment, 201412 acquisition €na of all assets of Enzyme Solution Unit of Enzymatics by Qiagen	2014-12-31
RiNA GmbH–NONE: investment, 201412–201506 bankruptcy AG Berlin-Charlottenburg 36R IN 4968/14 Massenunzulänglichkeit	2014-12-29
Pieris–SEVERAL: investment, 201412 private placement $13.56m with 6.8m shares common stock $2/share	2014-12-23
Pieris–Trout Group: public relations, 201412 service existent	2014-12-23
Bina Technologies–Roche: investment, 201412 acquisition of Bina by Roche	2014-12-19
Bruker Corp–Univ Alberta: mass spectra database, –201412 collab development of Bruker HMDB Metabolite Library	2014-12-19
Dutalys–Roche: investment, 201412 acquisition $133.75m upfront cash + $355m milestones	2014-12-18
OncoEthix–Merck (US): investment, 201412 acquisition $110m upfront + $265m milestones by Merck through a subsidiary	2014-12-18
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG	2014-12-18
Pieris–Marika: investment, 201412 reverse merger to list Pieris AG in US with Marika Inc renamed Pieris Pharmaceuticals Inc	2014-12-18
Emergent BioSolutions–Evolva: antibiotics, 201412 acquisition EV-035 series of broad spectrum antibiotics incl GC-072 for up to $70.5m plus royalties	2014-12-17
Humedics–BioMedPartners: investment, 201412 BioMedInvest-II LP fund joins Series C w approx €700k bringing round to €7m	2014-12-17
MeVis–Varian Medical Systems: investment, 201412–201504 public cash tender offer €30m with €17.5/share	2014-12-17
Sigma-Aldrich–Indi Molecular: PCC technology, 201412– collab €na to explore use of PCC technology w Sigma-Adrich’s biological tools	2014-12-17
Protagen–Qiagen: investment, 201412 financing round 1st closing of total volume €10m incl new investor Qiagen NV	2014-12-16
Protagen–SEVERAL: investment, 201412 financing round 1st closing of total volume €10m with Qiagen + MIG Fonds + NRW.Bank + management	2014-12-16
Annexon Biosciences–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures	2014-12-15
Annexon Biosciences–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF	2014-12-15
Annexon Biosciences–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter	2014-12-15
Annexon Biosciences–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures	2014-12-15
Deutsche Biotech Innovativ–SEVERAL: investment, 201412 capital increase €408.9k via private placement of 34,800 new shares with €11.75/share	2014-12-12
Genetrix (ES)–SEVERAL: investment, 201412 rights offering + private placement of Sygnis AG €4.95m with 2.476m new shares €2/share	2014-12-12
Takasago–Evolva: fermentation technology, 201412– collab developm production technology for flavours + fragrances	2014-12-11
Roche–AvanSci Bio: tissue dissection technology, 201412 acquisition all microdissection technology assets incl MilliSect system by Roche Dx	2014-12-10
Symphogen–Selexis: cell line development, 201412– license to SUREtechnology platform + SURE CHO-M Cell Line + collab RnD	2014-12-09
BioCat GmbH–Genetrix (ES): TruePrime, 201412– distribution non-excl of Sygnis’ TruePrime Single Cell WGA kit by BioCat	2014-12-08
KWS Saat–Metabolomic Discoveries: metabolomic services, 201412– supply service 3y to study + improve KWS crops on biochemical level	2014-12-05
Sigma-Aldrich–MIT: CRISPR technology, 201412– non-excl license to foundational CRISPR patents from Broad Institute	2014-12-04
Anergis–SEVERAL: investment, 201412 financing round Series B CHF14.5m (€12.1m) co-led by Sunstone Capital + BioMedInvest + Renaissance PME + WJFS	2014-12-03
Ariosa Diagnostics–Roche: investment, 201412 acquisition by Roche	2014-12-02
Ayoxxa–SEVERAL: investment, 201412 financing round Series B extension €2.3m from BioMedPartners AG + Grazia Equity GmbH	2014-12-02
Bayer–Orion Corp: cancer drug, 201412 existent collab ww developm + marketing of oral androgen receptor modulator ODM-201 for prostate cancer	2014-12-02
BioVersys–Enamine: drug discovery services, 201412– collab extension €na supply services for discovery of new antibiotics	2014-12-02
Xeltis–Kurma: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners	2014-12-02
Xeltis–Life Sciences Partners: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners	2014-12-02
Xeltis–SEVERAL: investment, 201412 financing round Series B €27m co-led by LSP + Kurma Partners plus VI Partners + current investors	2014-12-02
Xeltis–VI Partners: investment, 201412 financing round Series B totalling €27m incl co-investor VI Partners	2014-12-02
InnoLife project–EU (govt): grant, 201412– KIC grant of up to €700m out of a total project volume >€2b	2014-12-01
Nanolive–SEVERAL: investment, 201412 closing of 1st financing round	2014-12-01
Pieris–MacDougall Biomedical Communications: public relations, 201412 service existent	2014-12-01
Sartorius–SEVERAL: credit, 201412– syndicated €400m 5-year loan from bank syndicate led by BNP Paribas + Commerzbank + LBBW	2014-12-01
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana	2014-12-01
Uniqure–MacDougall Biomedical Communications: public relations, 201412 service existent	2014-12-01
Boehringer–NanoPET Pharma: contrast medium, 201411– collab development of contrast media for use in preclinical research	2014-11-30
WeissBioTech–BRAIN: investment, 201411 acquisition €na of majority shareholding in WeissBioTech GmbH by BRAIN AG	2014-11-27
Promethera–SEVERAL: investment, 201411 financing round Series C €20.33m incl new investors SFPI-FPIM + SMS Investments	2014-11-25
Promethera–Wallonia (govt): credit, 201411 loans + subisidies totalling €5m to support clinical development of HepaStem + collab w EMD-Millipore	2014-11-25
PS Biotech–SEVERAL: investment, 201411 financing round Series A	2014-11-25
Curetis–Life Sciences Partners: investment, 201411 financing round Series B extension totalling €14.5m incl €7m from new investors LSP-HEF + Qiagen	2014-11-24
Curetis–Qiagen: investment, 201411 financing round Series B extension totalling €14.5m incl €7m from two new investors Qiagen + LSP-HEF	2014-11-24
Curetis–SEVERAL: investment, 201411 financing round Series B extension €14.5m new investors Qiagen + LSP-HEF + all existing investors	2014-11-24
AstraZeneca–Biognosys: mass spectrometry services, 201411– supply Proteome-SEQ service to AstraZeneca	2014-11-21
BioNano Genomics–Novartis: investment, 201411 financing round Series C totalling $53m co-led by new investor Novartis Venture Fund	2014-11-20
Bionano Genomics–SEVERAL: investment, 201411 financing round Series C $53m co-led by new investors Legend Capital + Novartis Venture Fund	2014-11-20
MagForce–SEVERAL: investment, 201411 capital increase €10.2m placing 1.7m new shares €6/share	2014-11-20
NEU² project–Metabolomic Discoveries: biomarker discovery, 201411– collab to identify metabolomic markers for MS with Fraunhofer IME + UKE	2014-11-20
Roche–Axxam: drug discovery services, 201411– supply drug screening + assay development services by Axxam + HDC	2014-11-19
Allylix–Evolva: investment, 201411–201412 acquisition merger for 46m new Evolva shares representing 14.1% post-merger share	2014-11-18
Evolva–Cargill: investment, 201411 investment $4m to support merger acquisition of Allylix by Evolva	2014-11-18
Intellia Therapeutics–Atlas Venture: investment, 201411 financing round Series A totalling $15m led by Atlas Venture + Novartis	2014-11-18
Intellia Therapeutics–Novartis: investment, 201411 financing round Series A totalling $15m led by Atlas Venture + Novartis	2014-11-18
Intellia Therapeutics–SEVERAL: investment, 201411 financing round Series A $15m led by Atlas Venture + Novartis	2014-11-18
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery	2014-11-18
Pfizer–Merck (DE): antibody cancer drug, 201411– collab dev + commerc of anti-PD-L1 antibody $850m upfront + $2b milestones + shared costs + revenues	2014-11-17
Protagen–BioStrata: public relations, 201411 service existent by BioStrata	2014-11-17
Qiagen–Protagen: proteomic companion diagnostics, 201410– collab €na developm for autoimmune therapies using SeroTag platform	2014-11-17
Bruker Corp–Premier Biosoft: mass spectrometry s/w, 201411– distribution co-marketing + resale of SimLipid s/w + SimMet s/w by Bruker	2014-11-14
Cogent Healthcare–Fresenius: investment, 201411– acquisition €na of Cogent by Sound Physicians Inc ANNOUNCED	2014-11-13
Univ Furtwangen–Danaher: mass spectrometer, 201411 supply existent AB Sciex QTRAP 4000 system used by Prof Fath for water analysis	2014-11-13
Novartis–Qiagen: molecular companion diagnostics, 201411– collab €na master agreement devlepm + commercialisation of CDx for Novartis drugs	2014-11-11
Histide–SEVERAL: investment, 201411 financing round Series A CHF4.5m ($4.6m) led by Parter Capital + private investors	2014-11-10
Humedics–SEVERAL: investment, 201411 financing round Series C €6.3 led by new investors Vesalius Biocapital Partners + Seventure Partners	2014-11-10
Siemens–SEVERAL: investment, 201411 acquisition of Siemens Audiology Solutions for €2.15b plus earn-out by EQT + Strüngmann family	2014-11-06
Definiens–AstraZeneca: investment, 201411 acquisition $150m upfront + milestones by MedImmune	2014-11-04
Bruker Corp–Techcomp: investment, 201411 acquisition of GC + GC-SQ SCION business by Techcomp Europe Ltd	2014-11-03
Dihon Pharmaceutical–Bayer: investment, 201411 acquisition for CNY3.6b=€460m	2014-11-03
Covance–LabCorp: investment, 201411–201502 acquisition $6.2b w $107.19/share paid $75.76 in cash + 0.26886 LabCorp shares per Covance share	2014-11-02
EBOKON project–Germany (govt): grant, 201411–201512 BMBF grant €2.3m to DZIF + partners for Ebola virus research	2014-11-01
Servier–GeNeuro: GNbAC1 MAb, 201411– collab developm + marketing for MS w excl license option ww excl US+JP $47m upfront + $408 milestones + royalties	2014-11-01
MYR GmbH–High-Tech Gründerfonds: investment, 201410 financing round totalling €7.9m from Maxwell Biotech Venture Fund + HTGF	2014-10-31
MYR GmbH–Russia (govt): investment, 201410 financing round totalling €7.9m from Maxwell Biotech Venture Fund + HTGF	2014-10-31
MYR GmbH–SEVERAL: investment, 201410 financing round €7.9m from Maxwell Biotech Venture Fund + HTGF	2014-10-31
Deutsche Messe–Select Biosciences: European Lab Automation conference, 201410–201510 collab co-hosting of ELA 2015 + Labvolution 2015 in Hannover	2014-10-30
Bayer–DuPont: herbicides, 201410–201412 acquisition €na approx 30 herbicides for land management from DuPont Crop Protection by Bayer CropScience	2014-10-29
Eurofins–Igenbio: genomic services, 201410– collab product integration for one-stop-shopping solution by Eurofins Genomics + Igenbio	2014-10-29
Affimed–Distributed Bio: antibody technology, –201410 co-development of AbAccel technology platform with AbCheck	2014-10-28
Astellas–Qiagen: molecular companion diagnostics, 201410– collab €na master agreement devlepm + commercialisation of CDx for Astellas drugs	2014-10-28

1 2 3 ... 25 26 27 ... 54 55 56

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)